Table 3.
Author | Year | Overall survival | Progression-free survival | ||||
HR | 95%CI | P value | HR | 95%CI | P value | ||
Chen et al[21] | 2005 | 0.242 | 0.10-0.61 | 0.003 | - | - | - |
Chan et al[20] | 2009 | 0.412 | 0.27-0.63 | 0.0001 | - | - | - |
Riaz et al[27] | 2009 | 0.3712 | 0.13-1.011 | 0.0002 | - | - | - |
Vora et al[29] | 2009 | 0.952 | 0.73-1.231 | 0.88 | 0.482 | 0.15-1.451 | 0.09 |
Shao et al[28] | 2010 | 0.362 | 0.15-0.83 | 0.017 | 0.312 | 0.14-0.67 | 0.003 |
Kim et al[23] | 2011 | 0.432 | 0.29-0.65 | 0.001 | 0.482 | 0.33-0.70 | 0.001 |
Yau et al[30] | 2011 | 0.32 | 0.09-1.02 | 0.05 | 0.312 | 0.13-0.76 | 0.01 |
Kao et al[22] | 2012 | 0.1812 | 0.02-1.67 | 0.023 | - | - | - |
Lee et al[24] | 2012/H | 0.432 | 0.23-0.81 | 0.009 | 0.672 | 0.35-1.27 | 0.22 |
Lee et al[24] | 2012/C | 0.332 | 0.15-0.75 | 0.008 | 0.972 | 0.42-2.25 | 0.97 |
Memon et al[25] | 2012 | 0.142 | 0.02-0.83 | 0.03 | - | - | - |
Personeni et al[26] | 2012 | 0.522 | 0.31-0.85 | 0.009 | - | - | - |
Calculated result from data presented in article;
Multivariate result; -: Not performed; 2012/H: Hepatic arterial infusional chemotherapy study; 2012/C: Concurrent chemoradiation therapy study; HR: Hazard ratio; AFP: α-fetoprotein.